May 17, 2017
Dr. Taylor from Hartford Hospital, Dr. Pescatello from the UConn Department of Kinesiology and Dr. Puhl from the UConn Rudd Center are conducting a research study to compare the effects of a short-term encounter to media videos on measures of mental and physical heart health in women.
-
May 09, 2017
The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
-
May 09, 2017
Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, multicenter, open-label study which is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with Carboplatin + Nab-Paclitaxel compared with treatment with Carboplatin + Nab-Paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
-
May 09, 2017
The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks in patients with metastatic or locally advanced solid tumors.
-
May 09, 2017
This study is for participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC). Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, global, multicenter, open-label, study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of Atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC).
-
May 09, 2017
The purpose of this study is to describe patterns of care in CRPC (Castration-Resistant Prostate Cancer) patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.
-
May 09, 2017
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
-
May 09, 2017
Eligible patients who enroll in the study will be randomly assigned (by chance) to this double-blind, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV.
-
May 09, 2017
Eligible patients who enroll in the study will be randomly assigned to this multicenter, double-blind, placebo-controlled, parallel-group, superiority study comparing the efficacy and safety of Rivaroxaban with placebo for primary prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various cancer types who are scheduled to initiate systemic cancer therapy.
-
May 09, 2017
Eligible patients who enroll in the study will be randomly assigned to this multinational, double-blind, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of Bevacizumab-Pfizer plus Paclitaxel and Carboplatin versus Bevacizumab-EU plus Paclitaxel and Carboplatin in first-line treatment for patients with advanced non-squamous NSCLC.